ArticleNoro psikiyatri arsivi2026
Potential Epigenetic Mechanisms of High-Frequency rTMS in the Treatment of Major Depression: A Brief Report of Current Evidence.
Article in Noro psikiyatri arsivi, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Repetitive Transcranial Magnetic Stimulation (rTMS) is an FDA-approved, non-invasive neuromodulation technique with clinically supported efficacy in the management of treatment-resistant major depressive disorder (TRD). Although the clinical effectiveness of high-frequency rTMS applied to the left dorsolateral prefrontal cortex (DLPFC) is well established, the molecular mechanisms underlying its long-term therapeutic effects remain incompletely understood. The aim of this brief report is to examine the possible epigenetic modifications (DNA methylation, histone modifications, microRNA) associated with the antidepressant effects of rTMS in light of current literature, and to evaluate the dose-response relationship that may affect treatment response within the framework of homeostatic plasticity. Methods: A summary of current literature from the PubMed, Web of Science, and Google Scholar databases is presented using the keywords "rTMS," "major depression," "epigenetics," "histone modifications," "DNA methylation," "miRNA," and "homeostatic plasticity." Clinical and preclinical studies specifically investigating the molecular effects of rTMS on synaptic plasticity were included. Results: The reviewed studies suggest that rTMS may not merely provide transient electrical stimulation but may also operate through an "epigenetic regulatory" mechanism capable of permanently altering neuronal gene expression. In preclinical studies, changes in histone acetylation (e.g., regulation of CDK5 and PSD-95) and specific microRNAs (e.g., miR-146a-5p) have been observed to modulate synaptic plasticity. Furthermore, it has been proposed that the dose-response relationship of rTMS is non-linear; excessive stimulation may activate "homeostatic plasticity" mechanisms, thereby reducing synaptic sensitivity. Discussion: Current findings indicate that rTMS may exert an antidepressant effect by reorganizing synaptic plasticity through epigenetic modifications. Enhancing treatment efficacy depends on optimizing the dosage by considering homeostatic balances and integrating epigenetic biomarkers capable of predicting treatment response into clinical practice. Future personalized treatment protocols should be designed based on these molecular and neurophysiological insights.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.